|Mr. Leonard L. Mazur||Exec. Chairman & Sec.||363.75k||N/A||1945|
|Mr. Myron Z. Holubiak||Pres, CEO & Director||654.75k||N/A||1947|
|Mr. Jaime Bartushak||CFO & Chief Accounting Officer||395.56k||N/A||1968|
|Mr. Gary F. Talarico||Exec. VP of Operations||N/A||N/A||1955|
|Mr. Andrew Scott||VP of Corp. Devel.||N/A||N/A||N/A|
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction tissue expander infections following breast reconstructive surgeries; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.